Meta-Analysis:
Colorectal adenoma recurrence rates among postpolypectomy patients in the placebocontrolled groups of randomized clinical trials: a metaanalysis
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 2522 views | Full Text 4138 views
Xin Shi1,*, Zhiping Yang1,*, Qiong Wu1 and Daiming Fan1
1State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
*These authors contributed equally to this work
Correspondence to:
Zhiping Yang, email: [email protected]
Daiming Fan, email: [email protected]
Keywords: colorectal adenoma, placebo, recurrence, meta-analysis
Abbreviations: CRA: colorectal adenoma; CRC: colorectal cancer; RCT: randomized controlled trial; CI: confidence interval
Received: March 08, 2017 Accepted: April 14, 2017 Published: May 25, 2017
ABSTRACT
Background: Evidence regarding the benefit of therapy to prevent the post-polypectomy recurrence of colorectal adenoma is limited. Endoscopic recurrence is the main outcome according to an evaluation of trials involving recurrence prevention.
Aim: To estimate the recurrence rates of post-polypectomy colorectal adenoma in placebo-controlled arms of randomized clinical trials and to identify the prognostic factors influencing these rates.
Methods: We combined data from all randomized controlled trials evaluating therapies for colorectal adenoma using placebo from 1988 to 2016. The data were combined in a random-effects model. Primary outcomes were endoscopic adenoma and advanced adenoma recurrence of colorectal adenoma.
Results: The pooled estimates of the adenoma recurrence rates were 37% (95% confidence interval [CI], 33%-41%; range, 33%-52%) at 1 year, 47% (95% CI, 41%-54%; range, 46%-51%) at 2 years, 41% (95% CI, 33%-48%; range, 20%-61%) at 3 years, 48% (95% CI, 38%-57%; range, 37%-53%) at 4 years, and 60% (95% CI, 52%-68%; range, 48%-68%) at 5 years. The pooled estimates of the advanced adenoma recurrence rates were 10% (95% CI, 6%-15%; range, 7%-13%) at 1 year, 12% (95% CI, 8%-16%; range, 3%-19%) at 3 years, 14% (95% CI, 10%-18%; range, 13%-16%) at 4 years, and 14% (95% CI, 10%-19%; range, 9%-21%) at 5 years. Significant heterogeneity among the randomized clinical trials (P < 0.001) was observed for each recurrence rate.
Conclusions: This meta-analysis confirms the heterogeneity of recurrence rates among post-polypectomy colorectal adenoma patients who received placebo. No single design variable was identified that might explain the heterogeneity.